{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-101825","form_type":"8-K","ticker":"ORMP","cik":"0001176309","company_name":"ORAMED PHARMACEUTICALS INC.","filed_at":"2025-10-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.935380+00:00","generated_at":"2026-05-17T02:18:48.433886+00:00","sec_items":["1.01","1.02","2.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Oramed terminates HTIT joint venture, repurchases 1.15M shares, reports ~$210M in assets, launches new insulin trial","bullets":["Repurchased 1,155,367 shares from HTIT Biotech at $2.23/share for $2.58M total; shares cancelled.","Terminated joint venture with HTIT after it failed to satisfy closing conditions; oral insulin program to continue independently.","Preliminary unaudited cash and assets ~$210M as of Sep 30, 2025, up from $155.7M in Jan 2023.","Initiating 60-patient US oral insulin trial targeting high-responder subgroups (lower BMI, older) for >1% HbA1c reduction.","Investment portfolio: $27.1M unrealized gain on Alpha Tau ($64.8M position); Scilex loan returned $95.5M of $99.5M."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-101825","json":"https://secwatch.observer/filing/0001213900-25-101825.json","markdown":"https://secwatch.observer/filing/0001213900-25-101825.md","text":"https://secwatch.observer/filing/0001213900-25-101825.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1176309/000121390025101825/0001213900-25-101825-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1176309/000121390025101825/ea0262319-8k_oramed.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:18:48.433886+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}